Literature DB >> 23813652

Response to "Predictors of survival in thrombotic thrombocytopenic purpura" Haematologica 2013;98(5):e58.

Paul Coppo.   

Abstract

Entities:  

Keywords:  ADAMTS13; TTP-HUS; thrombotic thrombocytopenic purpura

Mesh：

Year:  2013        PMID： 23813652      PMCID： PMC3696600          DOI： 10.3324/haematol.2013.091504

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Deficiency of ADAMTS13 and thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Blood       Date:  2002-11-15       Impact factor: 22.113

2.  A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura.

Authors:  Marie Scully; Vickie McDonald; Jamie Cavenagh; Beverley J Hunt; Ian Longair; Hannah Cohen; Samuel J Machin
Journal:  Blood       Date:  2011-06-02       Impact factor: 22.113

3.  Predictors of survival in thrombotic thrombocytopenic purpura.

Authors:  Shruti Chaturvedi; Nirmanmoh Bhatia
Journal:  Haematologica       Date:  2013-05       Impact factor: 9.941

4.  Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases.

Authors:  A Veyradier; B Obert; A Houllier; D Meyer; J P Girma
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

5.  The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange.

Authors:  Melissa J Bentley; Chris M Lehman; Robert C Blaylock; Andrew R Wilson; George M Rodgers
Journal:  Transfusion       Date:  2010-04-20       Impact factor: 3.157

6.  Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience.

Authors:  Paul Coppo; Michael Schwarzinger; Marc Buffet; Alain Wynckel; Karine Clabault; Claire Presne; Pascale Poullin; Sandrine Malot; Philippe Vanhille; Elie Azoulay; Lionel Galicier; Virginie Lemiale; Jean-Paul Mira; Christophe Ridel; Eric Rondeau; Jacques Pourrat; Stéphane Girault; Dominique Bordessoule; Samir Saheb; Michel Ramakers; Mohamed Hamidou; Jean-Paul Vernant; Bertrand Guidet; Martine Wolf; Agnès Veyradier
Journal:  PLoS One       Date:  2010-04-23       Impact factor: 3.240

Review 7.  Thrombotic microangiopathies: towards a pathophysiology-based classification.

Authors:  Paul Coppo; Agnès Veyradier
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2009-03

Review 8.  Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.

Authors:  J Evan Sadler
Journal:  Blood       Date:  2008-07-01       Impact factor: 22.113

9.  Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients.

Authors:  Thomas Raife; Bonnie Atkinson; Robert Montgomery; Sara Vesely; Kenneth Friedman
Journal:  Transfusion       Date:  2004-02       Impact factor: 3.157

10.  ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients.

Authors:  Sara K Vesely; James N George; Bernhard Lämmle; Jan-Dirk Studt; Lorenzo Alberio; Mayez A El-Harake; Gary E Raskob
Journal:  Blood       Date:  2003-03-13       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.